An overview of the pathfinder clinical trials program: Long‐term efficacy and safety of N8‐GP in patients with hemophilia A
Author:
Affiliation:
1. Department of Transfusion Medicine Nagoya University Hospital Nagoya Japan
2. Haemophilia, Haemostasis and Thrombosis Centre Hampshire Hospitals NHS Foundation Trust Basingstoke UK
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14958
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cases of less‐than‐expected FVIII activity in previously treated patients during post‐marketing surveillance of N8‐GP;Haemophilia;2023-09-20
2. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A;Blood Advances;2023-02-21
3. Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study;Research and Practice in Thrombosis and Haemostasis;2022-02
4. Clinical outcomes after joint surgery in patients on turoctocog alfa pegol (N8‐GP) prophylaxis: A post hoc analysis;Haemophilia;2021-11-22
5. Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP);Patient Preference and Adherence;2021-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3